C.M. Bidwell & Associates’s Acadia Pharmaceuticals ACAD Stock Holding History

C.M. Bidwell & Associates’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,455	Closed	-$34.8K	–	519
2023 Q2	$34.8K	Sell	1,455 -150	-9%	-$3.33K	0.03%	323
2023 Q1	$30.2K	Buy	+1,605	New	+$30.6K	0.02%	336
2020 Q1	–	Sell	-875	Closed	-$37K	–	344
2019 Q4	$37K	Buy	+875	New	+$38.1K	0.03%	263

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

C.M. Bidwell & Associates's ACAD Position: Q3 2023 in Review

C.M. Bidwell & Associates sold out of Acadia Pharmaceuticals (ACAD) in Q3 2023, closing a stake of 1,455 shares — an estimated $34.8K sold.

C.M. Bidwell & Associates first reported a position in ACAD in Q4 2019 and held it in 3 quarters. The position peaked at $37K in Q4 2019. 248 funds tracked by Wall St. Rank hold ACAD as of Q3 2023.

C.M. Bidwell & Associates reported no remaining Acadia Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
C.M. Bidwell & Associates sold 1,455 Acadia Pharmaceuticals shares in Q3 2023, an estimated $34.8K.
C.M. Bidwell & Associates first reported a position in Acadia Pharmaceuticals in Q4 2019 and held it in 3 quarters.
C.M. Bidwell & Associates's Acadia Pharmaceuticals position peaked at $37K in Q4 2019.
248 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2023.

Based on C.M. Bidwell & Associates's 13F filing for Q3 2023, filed 13 Nov 2023.